Drug, bio-affecting and body treating compositions inventions 03/06

20060069010 - Detoxification depot for alzheimer's disease: The invention is directed to a device that is placed inside an Alzheimer's disease (AD) patient for the purpose of extracting and accumulating neurotoxic beta-amyloid peptides (nt-bAP) from body fluids. AD is the consequence of a process in which nt-bAP aggregates to form fibrils and plaques which can cause nerve...

20060069011 - Method for treatment and repair of meniscal injuries: A method for repair of meniscal injuries comprising induction of meniscal regeneration by introducing a strongly adhesive collagen-polyethylene glycol (PEG) hydrogel to a site of injury....

20060069012 - Methods and compositions for treating plasticity in a subject: Methods and compositions for at least maintaining plasticity in a system of a subject are provided. Embodiments of the subject methods include lowering long term potentiation in said subject in a manner effective to at least maintain plasticity of a system in said subject....

20060069008 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations...

20060069009 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the...

20060069013 - Pharmaceutical preparations comprising acid-stabilised insulin: Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed....

20060069016 - Cyclosporin alkyne analogues and their pharmaceutical uses: v

20060069014 - Inhibition of histone deacetylase as a treatment for cardiac hypertrophy: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by...

20060069015 - Novel cyclosporin analogues and their pharmaceutical uses: e

20060069017 - Somatostatin analog and uses thereof:

20060069023 - Animal model for studying hormone signalling and method of modulating the signalling: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signalling. The present invention further provides an animal model useful for screening for agents capable of agonizing or antagonizing hormone signalling. More particularly, the present invention...

20060069021 - Compositions and methods for intranasal administration of inactive analogs of pth or inactivated preparations of pth or pth analogs: Pharmaceutical compositions and methods are described comprising at inactive forms or parathyroid hormone peptide (PTH) or PTH analogs wherein the inactive forms are activated upon administration into the systemic circulation. Also described is a method of preventing local reaction to a biologically active agent, preparing a formulation comprising said biologically...

20060069019 - Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use: The disclosure provides a crystal structure of a complex of the HGF β-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met...

20060069022 - D-isomers of antimicrobial peptide: This invention provides D-isomers of MUC7-12-mer peptide of human saliva MUC7. The isomers have antimicrobial activity comparable to that of the L-isomers and are resistant to proteolysis. These peptides can be used as antifungal and antimicrobial agents....

20060069018 - Endogenous repair factor production promoters: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem...

20060069029 - Exendin analog formulations: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided....

20060069027 - Inhibitors of hepatitis c virus: The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins...

20060069020 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion...

20060069024 - Plant pr-5 proteins as mammalian therapeutic agents: Proteins of the PR-5 family having a lectin-like β barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like β barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues...

20060069025 - Survivin, a protein that inhibits cellular apoptosis, and its modulation: The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the...

20060069028 - Therapeutic agents and methods of use thereof for the modulation of angiogenesis: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to...

20060069026 - Treatment of obesity: A method for the treatment of obesity in an animal such as a human, comprises administering to the animal an effective amount of a peptide which comprises the carboxyl-terminal sequence of a growth hormone, particularly the carboxyl-terminal sequence of human growth hormone containing amine acid residues 177-191. A pharmaceutical composition...

20060069030 - Apolipoprotein a1 mimetics and uses thereof: The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol....

20060069032 - Beta-endorphin activity in cosmetics and dermatology: The subject of the invention is the use of at least one compound chosen from β-endorphin and β-endorphin-mimetic agents on the keratinocytes of the skin, for example in a cosmetic composition to enhance the barrier function of the skin, enhance its resistance to stress and in particular to pollution. It...

20060069031 - Use of gnrh agonists to support the luteal phase during infertility treatment: The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of women. According to this invention, the pharmaceutical agent is suitable to be used for supporting...

20060069034 - Antipathogenic benzamide compounds: e

20060069035 - Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy: The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of...

20060069033 - Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis: Use of distamycin, analogues and/or derivatives thereof in the manufacture of a pharmaceutical composition having activity against endoparasitosis in animals....

20060069036 - Methods of treatment of inflammation using glutathiones: Topical treatment of inflammatory skin diseases by application to affected skin areas of a composition containing glutathione. In the preferred embodiments of the invention, the glutathione is provided in a carrier at very high concentration levels, in the range of 16-70 percent by weight, more preferably 40-60 percent by weight....

20060069037 - Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors: This invention relates to peptide-containing α-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same....

20060069038 - Irreversible caspase-3 inhibitors as active site probes: The present invention encompasses a compound of Formula (I) useful as caspase active site probes. These probes can be used to determine whether a caspase has been activated, in cells or in tissues of animal models of various pathologies. Furthermore, through competition based assays, these caspase active site probes can...

20060069040 - Ghb compositions: The invention provides a combination of sodium gamma-hydroxybutyrate (GHB) or a prodrug or an analog thereof, with a compound that inhibits the metabolism of the GHB or GHB analog in vivo, thus prolonging or enhancing the bioactivity thereof....

20060069041 - Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents: The present invention discloses hydrophilic derivatives of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same....

20060069039 - Treatment of dyskinesia: The present invention relates to the treatment of dyskinesia with compounds of General Formula (I) such as topiramate. The compound may be topiramate or a derivative thereof. The dyskinesia may be associated with a basil ganglia-related movement disorder such as parkinsonism and may also arise as a side-effect of other...

20060069042 - Cytochrome p450 2c9 inhibitors: This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin,...

20060069043 - Chiral separation, characterization and biological action of optically active isomers of digoxin: Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV...

20060069044 - Modified glycosaminoglycans, pharmaceutical compositions and methods for oral delivery thereof: This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for...

20060069045 - Methods for treating familial dysautonomia: The present invention provides methods for modulating mRNA splicing in a normal or diseased cell or individual, e.g., elevating wild-type IKBKAP transcripts and the level of functional IKAP protein in an individual suffering from Familial Dysautonomia, by providing catechins, such as EGCG, to the cell or individual. The present invention...

20060069046 - Process for the production of (-)-epigallocatechin gallate: A process is provided for making (−)-epigallocatechin gallate (EGCG) by subjecting a green tea extract to chromatography on a macroporous polar resin, eluting EGCG from the resin with a polar elution solvent, optionally concentrating the eluate, optionally regenerating the resin by desorbing the remaining catechins, and optionally concentrating the desorbed...

20060069047 - Antibiotic conjugates: This invention features a compound of the following formula (I): wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agent via the bond or the linker, and the transportophore is an azithromycin...

20060069048 - Novel bicyclic 9a-azalide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20060069051 - Ache antisense oligonucleotide as an anti-inflammatory agent: Disclosed is a novel use for AChE antisense oligonucleotides as anti-inflammatory agents, wherein said oligonucleotides are preferably as denoted by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:7. Methods of treatment of inflammatory conditions, as well as fever, and particularly inflammation-associated neuropathies such as Guillain-Barré Syndrome, are described....

20060069058 - Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide: The present invention provides peptide analogs and peptide mimetics that inhibit pleated sheet formation in amyloid β-peptide, pharmaceutical compositions thereof and their therapeutic use. The inhibitory peptides possess activity as inhibitors in the formation of amyloid-like deposits and are useful in the treatment of Alzheimer's Disease....

20060069054 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060069055 - Delivery of polynucleotides: The present invention concerns methods and formulations for non-parental delivery of nucleic acid molecules to cells. In particular, the present invention relates to methods and formulations that enhance the transport of poly- and oligonucleotides across biological membranes....

20060069052 - Dna vaccines that expresses mutant adp-ribosyitransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity: The present invention provides DNA vaccines that direct the coincident expression of vaccine antigens coincidently with mutant ADP-ribosyltransferase toxins (mARTs), which display reduced, or are devoid of, ADP-ribosyltransferase activity, and methods for vaccinating animals with the same. In particular, the present invention provides DNA vaccines that direct the coincident expression...

20060069057 - Medicaments containing xenogeneic oligo- and/or polyribonucleotides: The invention relates to medicaments that contain xenogenic oligo- or/and polyribonucleotides as the effective component. The invention further relates to the use of said xenogenic oligo- or/and polyribonucleotides for treating herpesviridae infections and skin tumors....

20060069053 - Methods and compositions for enhancing cartilage repair: The invention relates to methods of enhancing repair of a cartilage and/or inducing formation of a cartilage by administering a cell, which expresses a factor of the T-box family, which includes inter-alia the brachyury. In another embodiment, the invention relates to an engineered cell, which is transfected with a vector...

20060069050 - Methods and compositions for mediating gene silencing: The present invention provides methods of conducting RNAi using siRNAs that are sequentially administered as single-stranded oligonucleotides. The siRNAs can be canonical or have non-canonical ends. The compositions and methods of the invention can bypass activation of interferon pathways and yet still efficiently and specifically activate RNAi/gene silencing. In another...

20060069049 - Methods and reagents related to foxo: The present invention relates to regulating the activity of Foxo and prevention and treatment of diseases associated with aberrant Foxo activity....

20060069056 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a...

20060069059 - Topical formulations for the treatment of depression with s adenosyl methionine: Disclosed herein are topical formulations for treating depression with S adenosyl methionine (SAM-e) The topical formulations contain at least 35% wt/wt of SAM-e partially dissolved in aqueous and lipophilic phases of an emulsion and the emulsion is stable from separation of phases for a period of at least 30 days...

20060069060 - Salts of decitabine: The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders....

20060069061 - Compositions containing uridine and choline, and methods utilizing same: The present invention is directed to methods of improving cognitive and neurological functions and increasing synthesis and release of neurotransmitters and membrane synthesis by neural cells and brain cells, comprising administering a composition comprising a uridine and a choline....

20060069062 - Diructose anhydride-containing composition and use thereof: The present invention relates to a difructose anhydride (DFA)-containing composition and use thereof. DFA is a cyclic disaccharide in which the reducing termini of two fructose molecules bind each other to hydroxyl groups at the other nonreducing termini. According to the present invention, it has been revealed that DFA is...

20060069063 - Crosslinked polygalacturonic acid used for postsurgical tissue adhesion prevention: Disclosed is a crosslinked PGA that is obtained by crosslinking PGA polymer with a crosslinking reagent to develop a three-dimensional crosslinked PGA structure. The crosslinked PGA has good tissue antiadhesion and biocompatibility....

20060069064 - Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using hyaluronic acid: Hyaluronic Acid (HA) is an essential component of tissue extracellular matrices that contributes to the architecture of stem cell niches, which determine the fate of stem cells. Decreased levels of HA are found in subjects experiencing a variety of pathological conditions, as well as in subjects receiving a variety of...

20060069065 - Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or...

20060069066 - Glycogen synthase kinase-3 inhibitors: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions....

20060069067 - Combination of an aromatase inhibitor with a bisphosphonate: The present invention provides a combination for the treatment of a disease or condition which responds to aromatase inhibition, in particular a proliferative disease, especially a malignant disease such as breast cancer or similar soft tissue endocrine-sensitive cancer, most preferably breast cancer, comprising an aromatase inhibitor and a bisphosphonate for...

20060069069 - Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses: A composition is provided which contains calcium chelators, bisphosphonates, and/or citrate compounds and which may be used for treating and or reducing pathological calcifications, heavy metal poisoning, the growth of Nanobacterium Calcifying Nano-Particles and calcification-induced diseases in humans and animals. The method includes administering a therapeutic composition of calcium chelators,...

20060069068 - Methods and compositions for the treatment of diseases characterized by pathological calcification: Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and...

20060069070 - Treatment of fibrosis using fxr ligands: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a...

20060069071 - Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations: Dermatitis can be effectively treated with the combined administration of dehydroepiandrosterone (DHEA) and a glucocorticoid. Systemic, topical and prepackaged DHEA-glucocorticoid embodiments are described....

20060069074 - Genetic predictor of efficacy of anti-asthmatic agents for improving pulmonary function: The present invention relates to methods for determining and predicting the efficacy of therapeutics for the treatment of an individual with asthma based on that individual's β2-adrenergic receptor. The invention finds particular applicability to the treatment of an individual with asthma with an inhaled corticosteroid or a leukotriene receptor antagonist...

20060069073 - Medicaments for inhalation comprising steroids and an anticholinergic: The present invention relates to novel pharmaceutical compositions based on steroids and salts of an anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints....

20060069072 - Method of male sexual enhancement: A method of sexual enhancement in men includes the steps of testing the blood of the man to determine the levels of free estradiol and free testosterone therein, assuring that the man's blood includes free estradiol within a first predetermined range and free testosterone within a second predetermined range, and...

20060069075 - Methods for treating dry eye: Methods of treating dry eye by administering fixed combinations of MUC-1 secretagogues, such as HETE derivatives, and anti-inflammatory steroids are disclosed....

20060069076 - Lxr/rxr-related methods and compositions: This invention provides methods for decreasing the amount of Aβ peptide produced by a neuronal cell comprising contacting the cell with an agent that, when in contact with the neuronal cell, causes activation of the cell's Liver X Receptor (LXR) and/or Retinoid X Receptor (RXR). This invention also provides for...

20060069078 - Management of ophthalmologic disorders, including macular degeneration: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell....

20060069077 - Receptor-type kinase modulators and methods of use: The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels...

20060069079 - Stable amorphous cefdinir: The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer)....

20060069080 - Combinations of substituted azetidinones and cb1 antagonists: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols....

20060069081 - Carbapenem antibacterials with gram-negative activity and processes for their preparation: The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of...

20060069082 - Novel substituted thiophenecarboxamides, their preparation and their use as medicaments: e

20060069083 - Pesticidal dibenzo(hetero)azepine derivatives: and Ra, Rb, Rc, Rd, Re′ Rf, Rf′ G, and p are as defined in the description; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; or the enantiomers or diastereomers, salts or esters thereof for combatting insects, arachnids, or nematodes, methods for...

20060069084 - Methods of inhibiting kinases: The present invention provides methods of inhibiting JAK involving the use of a group of compounds based either upon a 2-amino-6-carba-disubstituted pyrazine scaffold or a 2-amino-6-carba-disubstituted pyridine scaffold. The invention also provides methods of treating JAK-associated disease states....

20060069085 - Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones: e

20060069086 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to...

20060069087 - Histamine-3 receptor antagonists: as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound...

20060069088 - Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use...

20060069089 - Fungicides: Fungicidal compositions of the general formula (1): wherein one of W, X, Y and Z is N and the others are CR8; R8 is H, halo, C1-4 alkyl, C1-4 alkoxy or halo(C1-4)alkyl, provided that when X is CH, Z is N, R is NHNH2, R1 is phenyl and R2 is...

20060069090 - Triazine compounds: aryl, or heteroaryl; each of R2, R4, and R5, independently, is Rc, halogen, nitro, nitroso, cyano, azide, isothionitro, SRc, or ORc; R3 is Rc, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2, CORc, C(O)ORc, or C(O)NRcRd; n is 0, 1, 2,...

20060069091 - Oxazinones and methods for their use and synthesis: The invention pertains, at least in part, to new intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for their synthesis, and methods of using these compounds for the synthesis of...

20060069094 - Compositions and methods for treating cognitive disorders: Methods and pharmaceutical compositions relating to selective antagonists of the 5-HT6 receptor and 5-HT2A receptor useful for the treatment of cognitive disorders are presented....

20060069092 - Pharmaceutical compositions for the treatment of diseases related to neurotrophines: The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and/or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the...

20060069093 - Substituted 2h-1,3-benzoxazin-4(3h)-ones: Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient....

20060069095 - Azole derivatives: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, are disclosed. Also disclosed are methods of preparation of the above-mentioned compounds, pharmaceutical compositions and salts and esters thereof containing them, as well as the use of the above-mentioned compounds in the treatment, control or prevention of illnesses such as cancer....

20060069096 - Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma: Pyrazolo[3,4-e]benzoxazoles and analogues thereof for lowering intraocular pressure and treating glaucoma are disclosed....

20060069097 - Pyradazine compounds as gsk-3 inhibitors: The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use....

20060069098 - Bicyclic compound: wherein symbol “A” represents a saturated heterocyclic group, a 5-membered heteroaromatic group having two heteroatoms in the ring, a group represented by the formula A1 (R2, R3, and R4 represent hydrogen atom, hydroxyl group, etc.), etc., B represents a group represented by the formula B1 (R11 represents hydrogen atom, hydroxyl...

20060069099 - Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases: wherein variables Ra, R1, R2, R3, R4, A1, A4, L, Q, X and subscript n as described herein. The subject compounds are useful for treatment of inflammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are...

20060069100 - Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity: Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, the various forms...

20060069101 - Prodrugs of protein tyrosine kinase inhibitors: Novel compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as oncologic and immunologic disorders....

20060069102 - Novel heterocyclic nf-kb inhibitors: v

20060069103 - 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases:

20060069104 - Neurotrophic factor production accelerator: wherein R1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, and the above groups may be substituted with halogen, R2 is a hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, and the above groups may be substituted with halogen, A is —CO—, —SO2— or lower alkylene,...

20060069105 - Protein tyrosine kinase inhibitors: e

20060069106 - Tetrahydroquinazolin-4(3h)-one-related and tetrahydropyrido[2,3-d]pyrimidin-4(3h)-one-related compounds, compositions and methods for their use: wherein variables A1, A2, A3, A4, R1, R2, R3, R4, Q and L are as described herein. The subject compounds are useful for treatment of inflammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are useful...

20060069107 - Method of treating behavioral disorders: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like....

20060069108 - Use of (r)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases: A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a...

20060069109 - Therapeutic agents: A compound of the Formula: (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) Formula: (I); for use as a Tie2 receptor tyrosine kinase inhibitor in a warm-blooded animal such as man....

20060069110 - Substituted heterocyclic compounds and methods of use: The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult...

20060069111 - Compounds and methods for promoting smoking cessation: Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states....

20060069112 - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis...

20060069113 - Analgesic compositions containing buprenorphine: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine...

20060069114 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060069115 - Use of pde4 inhibitors as adjunct therapy for psychiatric disorders: The use of a PDE4 inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder....

20060069116 - 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also...

20060069118 - Crystalline forms of a factor xa inhibitor: The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1 (2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions....

20060069119 - Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones: e

20060069117 - Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same:

20060069120 - Novel piperidine derivaties as modulators of chemokine receptor ccr5: Compounds of formula (I): wherein R1, R2, R3, R4, R5, A and X are as defined herein; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal)....

20060069121 - (arylamidoanilino)nitroethylene compounds: or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R1, R2, and R5 are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular...

20060069122 - Chemokine-binding heterocyclic compound salts, and methods of use thereof: The present invention relates to chemokine-binding heterocyclic compound salts, methods of use thereof, and methods for preparing the same....

20060069123 - Substituted dipiperidine ccr2 antagonists: e

20060069124 - Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases: Methods of modulating eosinophil migration, chemotaxis or generation, in vitro, ex vivo, and in vivo are provided. Methods include contacting eosinophils with an amount of 5-HT2A receptor agonist or antagonist sufficient to modulate eosinophil migration, chemotaxis or generation....

20060069125 - Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride: The present invention provides a crystalline donepezil maleate, which is used as an intermediate in the preparation of donepezil hydrochloride. Also provided are novel processes for producing same in substantially pure form and a process for producing pharmaceutically pure amorphous donepezil hydrochloride therefrom....

20060069126 - Pharmaceutically active isoindoline derivatives: Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group, which may be further substituted in the 5-position with alkyl or halogeno, and in the 4-position with alkyl or a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNFα. A typical...

20060069127 - Imidazolo-related compounds, compositions and methods for their use: wherein variables R0, R1, R2, R3, R4, Q, L and subscript n are as described herein. The subject compounds are useful for treatment of infammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are useful for...

20060069128 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity: The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases....

20060069129 - Chemokine receptor binding heterocyclic compounds: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors...

20060069130 - Novel crystals: Obtaining the crystal of 4,6-dimethyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca2+ release-activated Ca2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions....

20060069131 - Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives: The present invention relates to novel combinations of fatty acid derivatives and pyridine carboxy derivatives, including fatty acid esters with glycerol and 3-carboxy pyridine derivatives such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed...

20060069132 - Azolecarboxamide herbicides: wherein J, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, T, U, W, Y and Z are as defined in the disclosure; and an effective amount of another herbicide or herbicide safener. Also disclosed is a method for selectively controlling undesired vegetation in a crop that involves contacting the locus...

20060069133 - Body weight gain inhibitor: The invention provides a pharmaceutical agent containing a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof, which shows superior effect for the suppression of body weight gain. In addition, the present invention provides such a pharmaceutical agent as does not increase body weights of...

20060069135 - Benzimidazole derivatives and their use for modulating the gaba-a receptor complex: e

20060069134 - Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same: The present invention provides a simple, practical, and industrially advantageous process for producing an optically active α-substituted cysteine or a salt thereof from inexpensive and readily available materials. The present invention provides a process for producing an optically active α-substituted cysteine or a salt thereof by converting a cysteine derivative...

20060069136 - Use of epothilones in the treatment of bone metastasis: The present invention relates to the use of Epothilones in the treatment of bone metastases and bone tumors or cancers, more particularly in treating, preventing or alleviating bone metastasis in a cancer patient....

20060069137 - Novel process for ezetimibe intermediate: The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]4-phenyl-2-oxazolidinone is reduced with (−)-DIP chloride to obtain 3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]4-phenyl-2-oxazolidinone....

20060069139 - Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,...

20060069138 - Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,...

20060069141 - Preparation of olmesartan medoxomil: The present invention provides a process for preparing olmesartan medoxomil....

20060069140 - Pyrazolone compounds and thrombopoietin receptor activator: A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a...

20060069144 - 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists: where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or...

20060069143 - 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists: where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or...

20060069142 - Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same: where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment...

20060069145 - Tricycles, their manufacture and use as pharmaceutical agents: e

20060069146 - Imidazole derivatives modulating the sodium channels:

20060069147 - Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors:

20060069148 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases....

20060069149 - Thiadibenzoazulene derivatives for the treatment of inflammatory diseases: The present invention relates to (a) novel 1-thiadibenzoazulene derivatives of the formula (I), (b) to their pharmacologically acceptable esters, salts and solvates, (c) to processes and intermediates for the preparation thereof, (d) to a process for preparing pharmaceutical formulations for the treatment of inflammatory diseases and conditions and (e) to...

20060069150 - Processes for preparation of crystalline mycophenolate sodium: Provided are crystalline mycophenolate sodium forms and processes for their preparation....

20060069151 - Novel use of lycopene: Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-can-cerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the...

20060069152 - Crystalline mycophenolate sodium: Provided are crystalline mycophenolate sodium forms and processes for their preparation....

20060069153 - Use of a class of antiviral compounds for production of an agent for the treatment or prevention of a viral infection in the respiratory tract: The invention discloses a use of dithiocarbamate compounds having the structural formula R1R2NCS2H, in which R1 and R2, independently of each other, represent a straight or branched C1-C4 alkyl, or, with the nitrogen atom, form an aliphatic ring with 4 to 6 C atoms, in which R1, R2, or the...

20060069154 - Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs: wherein: RN is independently C1-7alkyl; X1 is independently —I, —Br, or —Cl; X2 is independently —I, —Br, or —Cl; the group —N(CH2CH2X1)(CH2CH2X2) is independently attached at the 2-position or at the 4-position; each RG is independently —H or an ester substituent; n is independently an integer from 0 to 4;...

20060069155 - Method for reducing exacerbations associated with copd: This invention relates to a method for reducing the incidences and/or the severity of exacerbations of COPD by administering a phosphodiesterase 4 (PDE4) inhibitor....

20060069156 - Acylated aminopropanediols and analogues and therapeutic uses thereof: The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives....

20060069157 - Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as huntington's disease, by sodium butyrate chemotherapy: A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, includes administering a histone deacetylase (HDAC) inhibitor in a subject in need thereof. The HDAC inhibitor includes sodium butyrate....

20060069158 - Lipoxin compounds and their use in treating cell proliferative disorders: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed....

20060069159 - Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical...

20060069160 - Composition for treating bacterial, viral, fungal diseases, inflammation and pain: The present invention is directed to compositions and methods of treating bacterial, viral, fungal diseases; inflammation or inflammatory-related disorders; pain; and skin conditions. The composition comprises an organic solvent extract, which is prepared by the method comprising the steps of: (a) mixing methionine with water, (b) adding an aqueous hypochlorite...

20060069161 - Methods and reagents for the treatment of metabolic disorders: The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity....

20060069162 - Transparent eye drops containing latanoprost: An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least...

20060069163 - Method for treating alzheimer's disease: The present invention provides a method for treating or preventing the onset of Alzheimer's Disease comprising administering to a mammal in need thereof an Alzheimer's Disease-preventing or treating amount of a plasma-triglyceride level-lowering agent. Optionally, the plasma-triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent....

20060069164 - Process for preparing terbinafine by using platinum as catalyst: A process for the preparation of terbinafine, comprising the reaction of a compound of formula (II), or a salt thereof, wherein X is a leaving group, with tert-butylacetylene, in the presence of a platinum catalyst....

20060069165 - Treating morning hypertension by lowering morning blood pressure levels with propranolol: This invention relates to a method and kit having a composition for reducing morning blood pressure levels (for treating morning hypertension). Pursuant to this method, a therapeutic amount of β-adrenergic-blocking agent is administered nightly to a person that suffers from blood pressure level attacks such that the blocking agent is...

20060069166 - Laser treatment of cutaneous vascular lesions: Methods for treating maladies such as cutaneous vascular lesions. A patient in need of vascular lesion treatment is identified. A hyperosmotic agent is administered to a region adjacent the lesion. Blood flow velocity is slowed within the region using the hyperosmotic agent, and the lesion is exposed to laser radiation....

20060069167 - 1-chloro-2,4-dinitrobenzene gel compositions and methods for using the same: Gel compositions that contain 1-dichloro-2,4-dinitrobenzene (DNCB) are provided. Embodiments of the subject gel compositions include DNCB, an organic solvent and a viscosity agent, wherein the organic solvent and viscosity agent are inert with respect to the DNCB. Also provided are methods for using the subject compositions and kits for use...

20060069168 - Vascular embolization material: This invention provides an embolization material used for blocking a blood vessel in vivo for stopping the blood flow. The most suitable embolization material has a water swelling ratio of 30% or more, is degradable in a phosphate buffered saline, is formed as virtually spherical particles, and is preferably composed...

20060058219 - Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders: where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin,...

20060058221 - Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders: where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin,...

20060058217 - Compositions and methods for treatment of ovarian cancer: Compositions and methods for treatment of ovarian cancer are described. The compositions comprise antalamin, a compound that increases cytotoxic T-cell lytic activity at tumor sites. Methods of treatment for ovarian cancer are based on the administration of antalarmin to increase cytotoxic T-cell lytic activity or anti-tumor activity, which leads to...

20060058222 - Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders: A compound provided by the present invention includes an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently bonded to a biologically active peptide. One example of an inventive compound described is a conjugate of an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently coupled to an opioid peptide, such as...

20060058220 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are, disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of...

20060058224 - Methods of treating obesity with combination therapeutics: Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension with a combination of CNTF or a CNTF-related molecule and a second agent which is a therapeutic molecule useful in the treatment of obesity, type II diabetes, or other obesity-related...

20060058218 - Solid phase conjugation of complexing agents and targeting moieties: There is provided a technique for conjugating one or more complexing agents with a targeting moiety, such as natural amino acids, unnatural amino acids, peptides, peptide nucleic acids, nucleotides, and analogs and derivatives thereof. The one or more complexing agents are conjugated at one or more free amino groups of...

20060058223 - Taj in neuronal function: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist....

20060058225 - Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease: The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A2. The invention further relates to methods of identifying phospholipase A2 inhibitors and their use thereof for the prevention and/or treatment of...

20060058230 - Analogs of parathyroid hormone and pth-related protein as bone anabolic agents: The invention provides novel parathyroid hormone analogs and parathyroid hormones-related protein analogs. The invention also provides methods of using these analogs to treat osteoporosis, promote the formation of bone, and inhibit bone loss....

20060058231 - Bmp-7 variants with improved properties: The invention relates to variants of BMP-7 with improved properties and methods for their use....

20060058228 - Colon tumor specific binding peptides: Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM)...

20060058236 - Endogenously-formed conjugate of albumin: A conjugate formed in vivo and comprised of endogenous albumin and an amine-containing compound, such as a protein or a drug, is described. The conjugate is formed by in vivo cleavage of a polymer-dithiobenzyl-therapeutic agent conjugate to form an albumin-dithiobenzyl-therapeutic agent conjugate. The dithiol moiety of the albumin-therapeutic agent conjugate...

20060058238 - Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same: The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis....

20060058226 - Gd3-mimetic peptides: GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an anti-GD3 antibody; and medicinal compositions containing...

20060058227 - Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis: The present invention is based on the key roles played by Hedgehog proteins in the regulation of homeostasis of the adult intestinal epithelium. Ihh is expressed in the adult mammalian colon and provides a lineage-instructive signal and regulates colonic epithelial morphogenesis in a compartmental fashion. Loss of Ihh expression precedes...

20060058235 - Long lasting synthetic glucagon like peptide (glp-1): Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified...

20060058232 - Methods of treating cancer using a modified endostatin protein: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as...

20060058237 - P49/strap is a novel protein involved in gene regulation and cell proliferation: The invention provides isolated p49/STRAP protein, and isolated nucleic acids encoding a p49/STRAP protein. The inventors have discovered a new protein, named p49/STRAP that is expressed in cardiac tissue and other tissues in mammals. The p49/STRAP protein binds to serum response factor (SRF) and regulates transcription of SRF-responsive genes in...

20060058229 - Peptides and methods for cell death regulation: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide...

20060058233 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic...

20060058239 - Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders: The invention relates to the treatment of neurological disorders with the Insulin-like Growth Factor I (IGF-I) isoform known as mechano growth factor (MGF)....

20060058234 - Vegf traps and therapeutic uses thereof: Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells....

20060058240 - Peptides and compounds that bind to a receptor: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide...

20060058241 - Methods of treating disorders having a component of mercury toxicity: The present invention relates to methods of lowering the level of mercury in a subject, methods of lowering the level of mercury in a child diagnosed with autism and methods of assessing the risk of whether a child is susceptible of developing autism....

20060058242 - Dipeptide derivatives: e

20060058243 - Methods and compositions for treating diabetes mellitis: Methods for modulating diabetes, impaired glucose tolerance, gestational diabetes and glucose resistance in a mammal, particularly a human. In one embodiment the method comprises administering a gallotannin composition to a mammal in need of the same. The gallotannin composition comprises one or more select hydrolysable gallotannins. In another embodiment the...

20060058244 - New pyrazole derivatives and diabetic medicine containing them: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine....

20060058245 - Methods for treatment of thiol-containing compound deficient conditions: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing...

20060058246 - Macrolide compounds endowed with antiinflammatory activity: Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient....

20060058247 - Methods and compositions for treating cystic fibrosis: The present invention provides methods of using improved macrolide compositions in the treatment of cystic fibrosis. The macrolide compounds of Formulas 1-21 described herein may be used alone or in a cotherapeutic regimen with other agents that are active against cystic fibrosis. The present invention also provides compositions and methods...

20060058248 - Processes for the preparation of 6-11 bicyclic erythromycin derivatives: The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (IX-c):...

20060058249 - Efficient nucleic acid encapsulation into medium sized liposomes: A method for preparing liposomes containing at least one nucleic acid encapsulated therein comprising the following steps: (A) mixing a gel or a liquid containing gel particles with aqueous medium Z1 to directly form the liposomes containing the at least one nucleic acid encapsulated therein; (B)(i) mixing a gel or...

20060058250 - Methods of treating proliferative skin diseases using carbazole derivatives: The present invention relates to a method of treating a proliferative skin disease, comprising administering a therapeutically effective amount of a trk inhibitor....

20060058258 - Gene transcription and ionizing radiation: methods and compositions: The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of...

20060058254 - Immunostimulatory sequence oligonucleotides and methods of using the same: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides....

20060058257 - Influencing angiogenesis using cd66a: The invention relates to a method of influencing angiogenesis by administering a of a compound in a pharmaceutically compatible carrier selected from the group consisting of (i) CD66a, a CD66a variant, CD66a fragments or CD66a-derived glycostructures, or CD66a ligands, or (ii) of anti-CD66a specific antibodies and anti-sense oligonucleotides....

20060058252 - Methods and materials for treating human papillomavirus infections: The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers)....

20060058251 - Methods for treating and preventing infectious disease: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant....

20060058253 - Methods to reprogram splice site selection in pre-messenger rnas: The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct...

20060058256 - Oligoribonucleotides for the treatment of degenerative skin conditions by rna interference: The invention relates to oligoribonucleotides, which are capable of inducing breakdown of the mRNA enzymes that break down connective tissue, and to pharmaceutical and cosmetic compositions, which are provided for topical application and which contain the oligoribonucleotides. The compositions are particularly suited for treating degenerative skin disorders....

20060058255 - Rnai-based therapeutics for allergic rhinitis and asthma: The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of...

20060058259 - Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine: A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig...

20060058260 - Combination therapy with gemcitabine and zd6126: The present invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6126...

20060058261 - Chitin derivatives for hyperlipidemia: The preferred embodiments relate to chitin derivatives for prevention or treatment of hyperlipidemia, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The preferred embodiments are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal....

20060058262 - New injectable formulations containing progesterone: The present invention relates to injectable progesterone formulations and processes for their preparation....

20060058263 - Heat pasturized liquids containing glucosamine: The disclosure provides methods of making heat-pasteurized liquids, such as beverages, that contain glucosamine, wherein glucosamine is present in the beverage during the pasteurization process. The disclosure also provides liquids, such as beverages, made by these methods, as well as methods of using the glucosamine supplemented liquids, for example to...

20060058264 - Opioid receptor ligands and methods for their preparation: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. The invention also provides an improved method for isolating intermediate materials useful for...

20060058266 - Chemically modified oligonucleotides: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression....

20060058265 - Topical antiviral formulations: The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections....

20060058267 - Pharmaceutical compositions comprising a nos inhibitor: This invention relates to methods of treating neurodegenerative diseases and inhibiting neurological damage, comprising administering to a patient in need of such treatment an N-NOS inhibitor in combination with a GABA-A receptor modulator....

20060058268 - Compounds and methods for treating diabetic vascular diseases: i

20060058269 - Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation: A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate...

20060058270 - Ruthenium anticancer complexes: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer, wherein formula (I) is:...

20060058271 - Methods for screening, studying, and treating dissorders with a component of mercurial toxicity: The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental...

20060058272 - Pharmaceutical composition for use as a contraceptive: A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of...

20060058273 - Mastitis treatment: A pharmaceutical composition for intramammary administration to a nonhuman mammal comprising an antibacterial agent and prednisolone, wherein the composition comprises at least 20 mg of prednisolone, and its use for the treatment of clinical mastitis....

20060058274 - Use of an aldosterone receptor antagonist to improve cognitive function: Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed....

20060058275 - Processes for preparing stabilized, highly pure rocuronium bromide: Processes are provided herein for the preparation and purification of stable, powdered solids comprising substantially pure rocuronium bromide....

20060058276 - Processes for the preparation and purification of rocuronium bromide: Processes are provided herein for the preparation of pure rocuronium bromide and for the purification of impure rocuronium bromide obviating the need for column chromatography and that can be easily, conveniently and inexpensively scaled-up....

20060058277 - Use of oculosurface selective glucocorticoid in the treatment of dry eye: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of...

20060058278 - Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme in involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the...

20060058279 - Topical compositions comprising ascomycins: The present invention relates to a composition for topical administration comprising an ascomycin and a carrier vehicle vehicle comprising means to retain water in the outer skin layer and means to hinder water evaporating from the skin....

20060058280 - Preparation of penicillin procaine: A process for preparing penicillin G procaine comprises the steps of introducing inactive ingredients into a first mixing tank and sterilising the mixture of inactive ingredients in the first mixing tank. A procaine hydrochloride is dissolved in a second mixing tank, and the contents of the second mixing tank are...

20060058281 - Process for the preparation of cephalosporin antibiotic: An improved one-pot process for the preparation of Ceftiofur of the formula (I) or its salt, without isolating intermediate compound....

20060058282 - Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors: This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: —O—C(═O)— or —C(═O)—O— or —C(═O)—; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1...

20060058283 - Compositions comprising ubiquinones: The present invention provides antihyperlipidemic or antihypercholesterolemic compositions. These compositions ameliorate the adverse effects associated with other antihyperlipidemic or antihypercholesterolemic compositions. The present invention further provides methods of using the antihyperlipidemic or antihypercholesterolemic compositions....

20060058284 - Pyrrolidine and azetidine compounds as ccr5 antagonists: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency...

20060058285 - Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists: In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P and Neurokinin B by blocking the NK1, NK2 and NK3 receptors, the compounds according to the invention are useful as a medicine, in particular in...

20060058286 - Methods of treating hiv infection: The invention encompasses pharmaceutical compositions and methods for using Compound 1 or Compound 2 in combination with other agents for treating patients with AIDS or HIV infection....

20060058287 - Compounds: Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man....

20060058288 - Severe sepsis preventive therapeutic agent: p

20060058289 - Mercaptoimidazoles as ccr2 receptor antagonists: The present invention relates to a compound of formula (I) having CCR2 receptor antagonistic properties, particularly anti-infflammatory properties....

20060058291 - Cyclic oxyguanidine pyrazinones as protease inhibitors: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the...

20060058292 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized...

20060058293 - Combination of bupropion and a second compound for affecting weight loss: Disclosed are compositions for affecting weight loss comprising bupropion and a second compound, where the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions, antagonizes cannabinoid receptor activity, or is useful in the treatment of bipolar disorders....

20060058294 - Carboxamidine derivatives and their use in the treatment of vascular diseases: The invention relates to carboxamidine derivatives to pharmaceutical compositions containing the same and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases....

20060058295 - Novel compounds as pharmaceutical agents: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds....

20060058296 - Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase: The present invention provides a method to treat osteolytic lesions associated with multiple myeloma by the administration of one or more p38 MAP kinase inhibitors....

20060058298 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions....

20060058297 - Novel compounds useful for modulating abnormal cell proliferation: There is described compounds of Formulae I, II, III, IV and V. The compounds of Formulae I, II, III, IV and/or V are useful: in therapeutic methods and compositions for modulating cell proliferation, in diagnostic assays and as research tools....

20060058299 - N-2s-4-3,4-difluorobenzyl morpholin-2yl methyl -2-(3-methylsulphonyl amino!phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions: e

20060058300 - Intermediates of bupropion metabolites synthesis: Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed....

20060058301 - Modulators of ppar and methods of their preparation: The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases...

20060058302 - Benzamide, heteroarylamide and reverse amides: and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in...

20060058304 - Azaindole kinase inhibitors: and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through...

20060058303 - Imidazo-triazine derivatives as ligands for gaba receptors: A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions...

20060058305 - 3-phenyl-cinnoline homologue and antitumor agent containing the same: The present invention relates to a 3-phenyl-cinnoline analogue or a physiologically acceptable salt thereof, and a cell proliferation inhibitor and an antitumor agent comprising the same, as an active ingredient....

20060058306 - Solubilized topoisomerase poison agents: A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic...

20060058307 - Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog: The present invention relates to a combination of (a) an ATP-competitive inhibitor of Bcr/abl kinase activity and (b)) a tyrphostin analog, and the use of said combination or product for the treatment of bcr/abl-related diseases....

20060058309 - Respiratory syncytial virus replication inhibitors: The present invention concerns compounds of formula (I), prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof wherein -a1=a2-a3=a4- represents a radical of formula —CH═CH—CH═CH—; —N═CH—CH═CH—; —CH═N—CH═CH—; —CH═CH—N═CH—; CH═CH—CH═N—; wherein each hydrogen atom may optionally be substituted; Q is a radical of formulae (b-1), (b-2), (b-3),...

20060058308 - Vanilloid receptor ligands and their use in treatments: Substituted pyridines and pyrimidines and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints...

20060058310 - Remedies for vertebral canal stenosis: wherein all the symbols represent the same meaning as described in the specification; a salt of its acid when R3a represents hydrogen, or solvate thereof The therapeutic agent of the present invention is effective for prevention and/or therapy for spinal canal stenosis and the like, such as lumbar spinal canal...

20060058311 - Combinations for the treatment of diseases involving cell proliferation: wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of...

20060058312 - Stabilized aqueous preparation for injection: The present invention provides a stabilized aqueous preparation for injection containing 5-formyl-(6S)-tetrahydrofolic acid or a pharmacologically acceptable salt thereof as an active ingredient and a method of stabilizing 5-formyl-(6S)-tetrahydrofolic acid or a pharmacologically acceptable salt thereof. An aqueous preparation containing 5-formyl-(6S)-tetrahydrofolic acid or a pharmacologically acceptable salt thereof shows extremely...

20060058313 - Treatment of mesothelioma: The present invention relates to a method of treating a warm-blooded animal, especially a human, having mesothelioma, especially malignant mesothelioma, comprising administering to said animal a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative....

20060058314 - Oxazolidinone derivatives and their use as antibacterial agents: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: (I) wherein in (I) C is for example wherein A and B are independently selected from i) ii) and m is 1 or 2; R2b and R6b, R2a and R6a, R3a and R5a, are for...

20060058315 - 2-oxo-ethanesulfonamide derivates: Compounds of formula (I): Formula (I) wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described....

20060058316 - 4-oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition....

20060058317 - Oxazolidinone derivatives as antibacterial: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I), wherein C is selected from D and E, formula (D), formula (E), R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected...

20060058318 - Prodrugs of an erk protein kinase inhibitor: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders....

20060058319 - Pyrazolopyridines, process for their preparation and use as therapeutic compounds: e

20060058320 - [1,2,4] triazolo[1,5-c]pyrimidine derivatives: (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents a hydrogen atom, halogen, lower alkyl, lower alkanoyl, aroyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents lower alkyl, lower cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted...

20060058321 - Fused heterolaryl derivatives: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity....

20060058322 - Method of wound healing using a2b adenosine receptor antagonists: The present invention relates to methods of wound healing using A2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them....

20060058323 - New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions: e

20060058324 - 4-amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives: The invention relates to new 4-amino-5-phenyl-7-cyclohexyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof, alone or in combination with one or more other pharmaceutically active compounds, for the treatment of a disease, especially a...

20060058325 - Therapeutic quniazoline derivatives: Quinazoline derivatives of formula (I): wherein A is 6-membered heteroaryl containing a nitrogen atom and optionally containing one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy....

20060058326 - Pyrimidines, methods for the production thereof, and use thereof: R3 is a five- or six-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocycle which contains one to four heteroatoms from the group consisting of O, N and S; and processes and intermediates for preparing these compounds, compositions comprising them and their use for controlling phytopathogenic harmful fungi are...

20060058327 - Mitotic kinesin inhibitors: The present invention relates to tetrahydropyridine compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals....

20060058328 - Use of n-aryl diazaspiracyclic compounds in the treatment of addiction: Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at...

20060058329 - Pyrazole inhibitors of the transforming growth factor: The invention relates to novel pyrazole derivatives which are inhibitors of the transforming growth factor, (“TGF”)-β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and...

20060058330 - Rylene derivatives and their use as dyes: e

20060058331 - Abuse resistant opioid dosage form: The present invention pertains to a pharmaceutical dosage form comprising an opioid analgesic and a nontoxic N-methyl-D-aspartate receptor antagonist wherein the pharmaceutical dosage form is substantially free of an opioid antagonist The nontoxic N-methyl-D-aspartate receptor antagonist is present in an opioid euphoria-inhibiting amount to prevent or discourage abuse....

20060058332 - Analgesic compositions containing buprenorphine: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine...

20060058333 - Analgesic compositions containing buprenorphine: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine...

20060058334 - Preperation of desloratine: The present invention also provides a process for the preparation of substantially pure desloratadine by the process comprising acidic hydrolysis of a compound of formula 3 where R is selected from COR1, COOR1 wherein R1 is selected from branched or linear alkyl (1-6 C), cycloalkyl, alkenyl, alkynyl, aryl, aralkyl and...

20060058335 - Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments: e

20060058336 - Pharmaceutical composition for treatment of drug dependence: The present invention relates to the use of a medicinal substance capable of enhancing or disinhibiting the actions of acetylcholine, and provides a pharmaceutical composition for treating drug dependence comprising said substance as an active ingredient, and a method of treating drug dependence using the same....

20060058337 - Phenanthridine carbonyl phenols: The present invention relates generally to phenanthridine carbonyl compositions such as substituted phenanthridine carbonyl phenols and methods of using them....

20060058340 - Compounds modulating c-kit activity: Compounds with 7-azaindole core structure with activity toward the receptor protein tyrosine kinase c-kit, compositions useful for treatment c-kit-mediate diseases or conditions, and methods of use thereof, are provided. Further provided are methods of c-kit ligand identification and design....

20060058339 - Compounds modulating c-kit activity and uses therefor: Compounds with generic structure 5-((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-benzylpyridine-2-amine with activity toward the receptor protein tyrosine kinase c-kit, compositions useful for treatment c-kit-mediate diseases or conditions, and methods of use thereof are described....

20060058338 - [1,7]naphthyridines as pde4 inhibitors: in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-α release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and...

20060058341 - Thiazolopyridine kinase inhibitors: The present invention is directed to novel thiazolopyridines, pharmaceutical compositions thereof, and the use thereof as inhibitors of ATP-protein kinase interactions. The thiazolopyridine compounds have the following Formula (I):...

20060058342 - Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases: provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular,...

20060058344 - Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions: o

20060058343 - Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols:

20060058345 - Use of papaverine-like vasodilator and pharmaceutical composition: The invention concerns the use of papaverine-like vasodilator for the production of a pharmaceutical composition for the treatment of ophthalmological dysfunctions which are linked to circulatory disturbances of the eye or which are to be attributed to circulatory disturbances of the eye, wherein the pharmaceutical composition is to be applied...

20060058347 - Crystalline form for quinapril hydrochloride and process for preparing the same: An amorphous form of quinapril hydrochloride substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications formed from the said novel crystalline form of quinapril hydrochloride of formula (I). The crystalline quinapril hydrochloride is in the form nitroalkane solvate in which the nitroalkane is nitromethane, nitroethane and nitropropane....

20060058346 - Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions: The disclosure concerns novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions. The enantiomers of tetrahydroisoquinoline derivatives are provided which are useful in stimulating heart rate and hypotensive activity, inhibitory activity against platelet aggregation, and suppressive against inducible NO synthase. The enantiomers of tetrahydroisoquinoline...

20060058350 - Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient: An alkynyl-substituted azasugar derivative and a drug containing the same as an active ingredient are disclosed. This drug is useful as a preventive or remedy for insulin-independent diabetes, rheumatoid arthritis, osteoarthritis, sepsis, acquired immune deficiency syndrome (AIDS), graft-versus-host disease (GVHD), asthma, atopic dermatitis, and ulcerative colitis....

20060058348 - N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors: c) when the heteroatom contained in the group R1 is substituted, p is not zero; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein....

20060058351 - Novel ligands that modulate lxr-type receptors and cosmetic/pharmaceutical applications thereof:

20060058349 - Piperidinetriol derivatives as inhibitors of glycosyceramid synthase: Compounds of formula (I): wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase....

20060058352 - Piperidine amine compounds and their use: Compounds having the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, R6, R7 and Ar are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same....

20060058353 - Benzofuran derivatives, process for their preparation and intermediates thereof: Compound of formula (I) wherein A is selected from pyridin-2-yl or thiazol-2-yl and R1, R2 and R3 are as described in the specification and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase....

20060058354 - Conjugated aromatic compounds with a pyridine substituent: m

20060058355 - Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker: Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein...

20060058356 - Indolylmaleimide derivatives: s

20060058357 - Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke:

20060058358 - Pharmaceutical compositions for the treatment of hyper-proliferative disorders: This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I...

20060058359 - Compounds useful as pesticides: Compounds useful to control pests are provided....

20060058360 - Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors: There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from —)— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each...

20060058361 - Therapeutic diphenyl ether ligands: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated...

20060058362 - 7-amido-isoindolyl compounds and methods of their use: The invention encompasses 7-amido-isoindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples inlcude, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome....

20060058363 - Nitric oxide releasing selective cyclooxygenase-2 inhibitors: The invention encompasses novel compounds of Formula (I) and Formula (II), which are nitric oxide-releasing prodrugs useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I) or Formula (II)....

20060058365 - Compositions and methods for treatment of colitis: The present invention relates to the treatment of inflammatory bowel disease (IBD) and related gastrointestinal pathologies. This invention also relates to the treatment of cytokine-mediated diseases, including tumor necrosis factor-α (TNFα)-induced diseases and/or chemokine-mediated diseases. This invention also relates to treating an animal having a disease or condition associated with...

20060058364 - Treatment of dependence and dependence related withdrawal symptoms: A method for treatment of dependence and dependence related withdrawal symptoms caused by the discontinuation of subacute or chronic use of psychostimulant agents, to ease a patient's withdrawal from the psychostimulants with an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable ester or salt thereof....

20060058366 - Jnk inhibitor: [wherein R1 represents substituted or unsubstituted aryl or the like and R2 represents a hydrogen atom, NR3R4 (wherein R3 and R4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkanoyl or the like), carboxy, lower alkenyl or the like] or a pharmaceutically...

20060058367 - Synthesis of amines and intermediates for the synthesis thereof: The invention relates in a first embodiment to a method for the manufacture of esters of the formula (I), or especially of amides of the formula (II), wherein the symbols have the meanings given in the specification, as well as other intermediates and compounds useful in the synthesis of tryptamines...

20060058368 - Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors: R5a and R5b is C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or C1-6alkyl, optionally substituted on one or more atoms; R5a and R5b may also be hydrogen, aryl, Het1, Het2; R6 is hydrogen or C1-6alkyl optionally substituted on one ore more carbon atoms. It further relates to their use as broadspectrum HIV protease inhibitors,...

20060058370 - Methods for producing cyclic benzamidine derivatives: In the present invention, the methods of producing a fluorinated cyclic benzamidine derivative (A), or a salt thereof, comprise the step of reacting a specific novel compound with ammonia or imide. The methods of this invention for producing a morpholine-substituted phenacyl derivative (B), or a salt thereof, comprise reaction of...

20060058369 - Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors: A method of treating a warm-blooded vertebrate animal having a medical condition in need of treatment with a composition that exhibits PAI-1 inhibition activity is disclosed. The method includes the steps of administering a treatment effective amount of the composition to a warm-blooded vertebrate animal having a medical condition selected...

20060058371 - Nf-kb inhibitors: The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated....

20060058372 - N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them: The present invention relates to a compound of the formula (I): in which T, A, R, B Xi, Yi and n are as defined in Claim 1, and to the pharmaceutically usable derivatives, solvates and stereoisomers thereof, comprising a mixture thereof in all proportions, which can be used in the...

20060058373 - Novel substituted sulfamate anticonvulsant derivatives: e

20060058374 - Urotensin ii receptor agents:

20060058375 - Method of treating dry eye disorders and uveitis: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis....

20060058376 - Composition having autonomic nerve modulating activity and method of use thereof: A composition having autonomic nerve function regulating action, comprising sesamin and/or episesamin as an active ingredient, is provided....

20060058377 - Novel compounds and methods for inhibiting cellular responses to hypoxia: c

20060058378 - Reduced bioirritant composition: A method for reducing irritancy of ascorbic acid administered to a biological surface for anti-angiogenic, anti-oxidant, anti-inflammatory and other effects. It has been discovered that pH neutralized ascorbic acid retains the efficacy of non-pH neutralized ascorbic acid in reducing neovascularization, providing an anti-oxidant effect, etc. but is less irritating and...

20060058379 - Connexin 26 inhibitor and cancer metastasis inhibitors: where R is a hydrogen atom or a hydrocarbon group, X is one of a hydrogen atom, a methansulfonyl group, an ethansulfonyl group, an acetyl group, a trifluoroacetyl group, a hydroxyl group, an alkoxy group and an amino group; m is an integer of from 4 to 10; and n...

20060058380 - Novel aminobenzophenone compounds: e

20060058382 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia....

20060058381 - Pharmaceutical formulation comprising (r)-bicalitamide: The present invention relates to a pharmaceutical formulation comprising the drug 4′-cyano-α′,α′,α′-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide in a solid dispersion with an enteric polymer having a pKa from 3 to 6, wherein >50% of the drug is provided in the form of the R-enantiomer. The invention also relates to a daily pharmaceutical dose of...

20060058383 - Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents: The present invention is directed to compositions that inhibit glycolysis, perferentially in cancer. Specifically, the anticancer compositions comprise 3-halo-2-oxopropionate and its derivatives, such as ester derivatives. However, in specific embodiments, the anticancer composition is sodium 3-halo-2-oxopropionate, such as sodium 3-bromo-2-oxopropionate and a stabilizing agent, such as carbonic acid. In particular...

20060058384 - Treatment of iga nephropathy with omega-3 fatty acids: A statistically significant benefit is observed in the treatment of IgA nephropathy by administration of Omega-3 fatty acids in a dosing regimen dependent on the size of the patient....

20060058385 - Combination of antidiabetic drugs: The combination of R-4-trimethylammonio-3-(tetra-decylcarbamoyl)-aminobutyrate and metformin is disclosed. Said combination of anti-diabetic drugs exerts a synergic action and allows the administration of the two drugs at doses such as to avoid or reduce the occurrence of side effects. The combination is also useful for improving the therapeutic cover far from...

20060058387 - Composition and method for treating skin conditions: Compositions and methods for treatment of skin conditions, such as age spots, liver spots, photodamaged skin, skin folds, diminished hair growth, non-infectious cellulite and “orange skin”, or for repairing damaged DNA in a skin cell, utilize a formulation including about 0.01-1 part by weight tretinoin, and about 1-45 parts by...

20060058386 - Painless injectable compositons containing salts of 2-arylpropionic acids: Pharmaceutical compositions are described, containing an alkylammonium salt of a 2-arylpropionic acid, which are suitable for parenteral administration and do not generate pain upon injection. The compositions contain preferably ketoprofen, ibuprofen, naproxen or tiaprofenic acid in aqueous solution at pH in the range between 8 and 9. The alkylammonium salt...

20060058388 - Methods for treating ocular diseases via introxide and or polyhydroxy acid containing compounds: Methods for prevention or treatment of ocular diseases via administration of a nitroxide and/or polyhydroxy acid containing compound are provided....

20060058389 - Novel compounds that inhibit factor xa activity: t

20060058390 - D-methionine formulation with improved biopharmaceutical properties: The present invention provides pharmaceutical suspensions of D-methionine in which the aqueous solubility of D-methionine is exceeded, thereby allowing oral administration of higher doses. The present invention also provides processes for preparing these suspensions. The present invention further provides methods for preventing, treating, or ameliorating oral mucositis, hearing loss due...

20060058391 - Calcilytic compounds: Novel Calcilytic compounds and methods of using them are provided....

20060058392 - Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase: The invention concerns a novel therapeutic application of rhein and diacerhein. Rhein and diacerhein, as well as the salts and esters thereof, can be used for treating diseases requiring a rise in the rate of the heme oxygenase enzyme, providing prevention and inhibition of stress on cells and tissues, and...

20060058393 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia....

20060058394 - Medicine of post-traumatic stress disorder: The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds (EP1 agonists), which activate EP1 receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP1 agonists such as (13E)-(11α,15S,17S)-2,5-ethano-6,9-dioxo-11,15-dihydro-17,20-dimethylprosta-13-enoic acid, PGE1, or PGE2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD)....

20060058395 - Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy: This invention relates to the use of certain compounds for the treatment of diseases that are responsive to antiangiogenetic therapy. Excessive angiogenesis occurs in diseases such as cancer, diabetic blindness, age-related macular degeneration, rheumatoid arthritis and psoriasis. The compounds are particularly useful for anti-metastatic treatment or for the treatment of...

20060058396 - Amide compounds for the potentiation of cholinergic activity: i

20060058397 - Fungicides: The use as a plant fungicide of a compound of the general formula (1): wherein X and Y are both chloro, bromo or methyl or X is methoxy and Y compounds (1), other than those where X and Y are both chloro or methyl and R1 is ethyl, are novel....

20060058398 - Medicinal compositions containing vitamin k's as nerve growth factor potentiator and utilization thereof: To provide medicinal compositions containing an active ingredient which has a low molecular weight, is free from any side effects and has an effect of potentiating nerve growth factor activity and utilization thereof for treating diseases associated with dementia, medicinal preparations containing an effective amount of vitamin K and/or its...

20060058399 - Emulsion preconcentrates containing cyclosporin or a macrolide: This invention provides an emulsion, e.g., microemulsion, pre-concentrate comprising a difficultly soluble active agent and a carrier medium. The active agent may, e.g., be a cyclosporin or a macrolide....

20060052278 - Diagnosis and treatment of human dormancy-related sequellae: New methods for diagnosis and treatment of human dormancy syndrome-related sequellae are provided. Human dormancy syndrome (HDS) is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects. HDS includes fibromyalgia, chronic fatigue, cancer, autoimmune disease, obesity and related dormancy conditions. Dormancy and HDS-related sequellae are...

20060052279 - Labeling proteins with dyes that are insoluble or only sparingly soluble in water: The proteins in a biological sample that is sought to be analyzed for its protein composition by an electrophoretic or chromatographic procedure are coupled to a dye in an unusually efficient manner by combining the sample with a solid dry composition containing the dye, a buffering agent, and in preferred...

20060052282 - Diagnostic and therapeutic means for pathologies associated with alpha 2 subunit of the na, k pump: A nucleic acid is described that comprises at least one segment of the gene encoding a functional segment of the alpha 2 subunit of the Na,K pump (ATPase, ATP1A2) for use in the diagnosis or treatment of pathologies associated with migraine or with alternating hemiplegia of the childhood. Appropriate diagnostic...

20060052280 - Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases: The present invention discloses the differential expression of golgin-245 in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk...

20060052285 - Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of...

20060052284 - Novel peptide conjugates: e

20060052281 - Protein s protects the nervous system from injury: Protein S is a significant neuroprotectant when administered after focal ischemic stroke and prevents hypoxic/re-oxygenation injury. Purified human plasma-derived or recombinant protein S improves motor neurological function after stroke, and reduced brain infarction and edema. Protein S also enhances post-ischemic reperfusion and reduced brain fibrin and neutrophil deposition. Cortical neurons...

20060052283 - The sperm binding ligand hiprty and its involvement in embryo cleavage: A sperm-binding ligand sequence with the amino acid sequence HIPRTY is claimed. Using proprietary bio-informatic analysis, this sperm-binding ligand sequence was shown to also precisely correspond with a previously characterized highly conserved protein-protein interaction site in the Axin protein at position 370 to 375. The Axin protein sequence HIPRTY is...

20060052286 - Factor vii conjugates for selectively treating neovascularization disorders: Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD,...

20060052287 - Polyethylene glycol - peptide copper complexes and compositions and methods related thereto: This invention relates to compositions comprising polyethylene glycol molecules coupled to peptide copper complexes, and, additionally, to such compositions formulated for use as pharmaceutical and cosmetic products, as well as to medical devices that comprise such compositions....

20060052288 - Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor: A pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2...

20060052289 - Use of somatostatin analogs in sleep apnea: Somatostatin analogues, e.g. comprising an amino acid sequence of formula -(D/L)Trp-Lys-X1-X2- wherein each of X1, and X2 is an amino acid residue as disclosed in the specification, have interesting properties in the treatment of sleep apnea....

20060052290 - Deuterated cyclosporin analogs and their use as immunomodulating agents: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution...

20060052292 - Adiponectin fragments and conjugates: The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position...

20060052291 - Chemically-modified progenipoietin conjugates: The present invention provides a chemically modified Progenipoietins (ProGPs) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting neutrophil-increasing activity than that of the un-modified ProGP, enabling reduced dose and scheduling opportunities....

20060052293 - Complex of a human foxc2 protein and a foxc2-interacting protein: The present invention relates to complexes of the FOXC2 protein with other proteins, in particular complexes of FOXC2 with proteins designated p621, NOLP, HSC71, FTP3, CLH1, and Kinase A Anchor Protein 84/149 (AKAP). The protein complexes can be used in methods of identifying agents useful for the treatment of medical...

20060052306 - Gras composition for enhanced mucosal delivery of parathyroid hormone: What is described is an aqueous pharmaceutical composition for intranasal delivery of PTH, comprising a PTH molecule, and one or more excipients selected from the group consisting of a chelating agent, an alcohol, and a surface active agent, wherein the PTH molecule selected from the group consisting of SEQ NO:...

20060052300 - Human kunitz-type inhibitor with enhanced antifibrinolytic activity: A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2)....

20060052295 - Intrathecal and intratumoral superantigens to treat malignant disease: The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral...

20060052304 - Method for remodeling bone and related sutures: The invention relates to the discovery that relaxin receptors exist in bone and related sutures. As such, bone can be remodeled, repaired, removed or grown. Particularly, the invention pertains to a method for modifying a target bone by administering a relaxin compound which binds to relaxin receptors and by monitoring...

20060052296 - Method of cell growth inhibition with agnoprotein: The growth of normal and abnormally proliferating cells can be inhibited by the introduction of agnoprotein, or biologically active fragments or derivatives of agnoprotein, into the cell in the absence of any other polyoma virus protein or viral replication....

20060052305 - Method of treating osteoporosis using intranasal parathyroid hormone: What is described is a method for treating osteoporosis in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation to the mammal wherein the PTH formulation is an aqueous formulation comprised of a PTH peptide and one or more excipients selected from the group consisting of...

20060052297 - Method of up-regulating tumor antigen expression using thymalfasin: The present invention provides a method for up-regulating tumor cell antigen expression, comprising administering to the cells an amount of thymalfasin sufficient to increase the expression of TLP relative to that of untreated tumor cells. Also provided are methods for enhancing the sensitivity of a immunodiagnostic or immunotherapeutic method, comprising...

20060052299 - Mntf peptides and compositions and methods of use: The present invention is directed to novel peptides and compositions capable of modulating viability and growth in neuronal cells, and to methods of modulating neuronal cell viability and growth employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to novel peptide analogues of...

20060052294 - Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin: The present invention refers to muteins of the C5a anaphylatoxin (C5a) which are C5a receptor antagonists, to nucleic acid molecules comprising a nucleotide sequence encoding such muteins of C5a anaphylatoxin, to host cells containing a nucleic acid molecule comprising a nucleotide sequence encoding such muteins of the C5a anaphylatoxin as...

20060052302 - Polymer factor ix moiety conjugates: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the...

20060052301 - Splice variants of peptide yy, neuropeptide y, pancreatic peptide y and amylin, and uses thereof: The present invention relates to alternative splice variants of Amylin and members of the Pancreatic Polypeptide family, namely PYY, NPY, and PPY, vectors and compositions that include the same, and methods of use thereof. This invention provides peptides, nucleic acid sequences which encode same, analogs and derivatives thereof, antibodies which...

20060052298 - Use of stable glutamine derivatives to improve drug absorption: The present invention relates to compositions and their use to enhance the uptake of pharmaceutical agents administered to mammalian species, including humans. More particularly, the present invention is directed to the administration of glutamine and stabilized glutamine derivatives to enhance the uptake of orally administered therapeutic agents....

20060052303 - Use of thyrotropin for regeneration of bone: The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imprerfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, high levels of endogenous thyrotropin, and long-term use of corticosteroids. The disclosed...

20060052307 - Bone growth factor: e

20060052308 - Transglutaminase inhibitors and methods of use thereof: Transglutaminase inhibitors and methods of use thereof are provided....

20060052310 - Regulation of substrate activity: A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment....

20060052309 - Use of convertase inhibitors in the treatment of fibrosis and scarring: The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions....

20060052312 - Paclitaxel hybrid derivatives: Methods and compositions for treating cancer patients that include administering at least one or more hybrid derivatives of paclitaxel that simultaneously display improved aqueous solubility, chemical stability under physiological conditions, a decreased liability toward multi-drug resistance, and in certain instances enhanced selective toxicity toward cancer cells compared to normal cells....

20060052311 - Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap): t

20060052315 - Cb 1/cb 2 receptor ligands and their use in the treatment of pain: Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein Ar1?, Ar2?, R1?, R2?, n and X are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060052314 - Pharmaceutical combination: There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivateive thereof) or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 or WO 01/28993 or (2) compound of claim...

20060052313 - Selective dipeptide inhibitors of kallikrein: e

20060052316 - Ceramide derivatives as modulators of immunity and autoimmunity: α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are...

20060052317 - Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also...

20060052318 - Tyrosinase activity cntrolling agent, process for producing the same and external preparations containing the same: Disclosed is a tyrosinase activity controlling agent comprising, as an active ingredient, a compound that has tyrosinase inhibiting or promoting activity, an external preparation comprising the controlling agent, and a process for producing the compound....

20060052327 - Cell specific gene silencing using cell-specific promoters in vitro and in vivo: Cell-specific methods for silencing genes using double-strand inhibitory RNA (iRNA) are provided, as are constructs for carrying out the methods....

20060052322 - Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent: The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers...

20060052328 - Connective tissue growth factor-2: The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of...

20060052320 - Mammalian genes involved in rapamycin resistance and tumorgenesis annexin xiii genes: The present invention provides methods and compositions for regulating rapamycin resistance and/or tumorgenesis by modulating the expression and/or the activity of annexin XIII gene. The invention also provides methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression and/or activity of annexin XIII gene. The invention also...

20060052323 - Method to inhibit cell growth using oligonucleotides: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or...

20060052324 - Methods and compositions for cell activation: Methods and compositions for activating a cell are provided. In practicing the subject methods, a cell including a coding sequence for either a telomerase reverse transcriptase (TERT) or a telomerase RNA component (TERC) is activated by conditionally increasing expression of the coding sequence. Also provided are transgenic animals and systems...

20060052321 - Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer: A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 98P4B6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The...

20060052329 - Regulation of human p2y1-like g protein-coupled receptor: Reagents which regulate human P2Y1-like G protein-coupled receptor can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, CNS diseases such as Parkinson's...

20060052319 - Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes: This invention relates to the fields of molecular biology and oncology. More particularly, this invention relates to the sensitization of cancerous cells to therapeutic agents. The invention provides methods, compositions, and formulations for potentiating or enhancing the toxicity of various cytotoxins and oxidizing agents, and of reducing the resistance and...

20060052325 - Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution: A retroviral vector for gene reconstitution is provided that includes a 3′ portion of a heterologous nucleic acid sequence 5′ of a first att site of the retroviral vector, a 5′ portion of the heterologous nucleic acid sequence 3′ of a second att site of the retroviral vector. In this...

20060052326 - Werner's syndrome helicase as a target for anti -hiv/aids therapy: Werner's Syndrome helicase (WRN) interacts in Tat/TAR-RNA chromatin-remodeling complexes assembled on the HIV-1 LTR to promote transcriptional activation and viral replication. WRN markedly increases basal HIV-1 transcription and synergizes with Tat to support LTR trans-activation. Inhibition of WRN functions, through expression of the trans-dominant-negative WRNK577M mutant, potently represses HIV-1 LTR...

20060052331 - 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity: r

20060052330 - Partial and full agonists of a1 adenosine receptors: Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction....

20060052333 - Method of treating arrhythmias: Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an Al adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside....

20060052332 - N-pyrazole a2a receptor agonists: t

20060052334 - Sequential therapy comprising a 20(s)-camptothecian and a pyrimidine base analog: A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base...

20060052335 - Chondroitin synthetase and dna encoding the enzyme: A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferase activity and N-acetylgalactosamine transferase activity....

20060052338 - N-acyl and quaternary ammonium modified polysaccharide fibers: This invention relates to novel N-Acyl and N-Alkyl modified quaternary ammonium polysaccharide fibers, or both N-Acyl and N-Alkyl modified quaternary ammonium polysaccharide fibers and pharmaceutical compositions comprising the modified fibers. Further the invention relates to processes for using such modified polysaccharide fibers to lower cholesterol, to lower a mammal's absorption...

20060052339 - N-acyl modified polysaccharides and pharmaceutical compositions comprising same and dietary calcium: This invention relates to novel N-acyl modified polysaccharides and pharmaceutical compositions comprising the modified polysaccharides and comprising dietary calcium as a mixture or as a salt. Further the invention relates to processes for using such compounds to inhibit lipases, to lower cholesterol, to lower the absorption of dietary fat, or...

20060052337 - Polysaccharide and composition from antrodia camphorata and use thereof: The invention relates to polysaccharide extracted from Antrodia camphorata and the method for preparing the polysaccharide. The invention also relates to compositions and methods for hepatoprotective effect....

20060052336 - Process for preparing a sterile high molecular weight hyaluronic acid formulation: A process for preparing a sterile ready-to-use aqueous pharmaceutical formulation comprises a high molecular weight hyaluronic acid salt (HA) at a specified concentration, comprising the steps of: providing an aqueous formulation comprising high molecular weight HAat a concentration of less than the specified final concentration; passing said aqueous formulation through...

20060052340 - Ophthalmic solution: It is an object of the present invention to provide an ophthalmic solution, which provides an enhanced comfort by suitably exhibiting an moisturizing effect to an eye and advantageously preventing an occurrence of unpleasant feelings caused by fluctuation of visual acuity. The ophthalmic solution of the present invention is provided...

20060052341 - Control of a biological function: A biological function is controlled via the autonomous delivery of formulations administered at a single site, by determining each of the preferred formulations having efficacy in effecting control of at least one stage of a preferred biological function and includes features of improved permeation of formulations to effect desired bioavailability...

20060052342 - Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups: The invention relates to aldonic acid esters of starch fractions or starch fraction derivatives which are selectively oxidised on the reducing chain end to form aldonic acids, and to solids and solutions containing said aldonic acid esters. The invention also relates to methods for producing said aldonic acid esters, to...

20060052343 - Anthranilamide insecticides: wherein A is O or S(O)?m#191;J is a phenyl or heterocyclic ring as defined herein; and R1 through R12, n, m and r are as defined in the disclosure. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective...

20060052344 - Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone): A compound of formula (I) wherein one of X and Y is silicon, and the other is carbon or silicon; Z is oxygen, sulphur or —N(R)—, wherein R is hydrogen or alkyl; R1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl; and R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,...

20060052346 - Nucleoside phosphonate derivatives useful in the treatment of hiv infections: The present invention relates to a method of treating HIV infections by administering a nucleoside phosphonate derivative represented by formula (1)....

20060052345 - Quinazolinone compounds as calcilytics: Various calcilytic compounds and pharmaceutical compositions containing these compounds are disclosed. Calcilytic compounds are compounds capable of inhibiting calcium receptor activity. Techniques which can be used to obtain calcilytic compounds and uses of calcilyitc compounds as calcium receptor antagonists are also disclosed....

20060052347 - Geranylgeranyl pyrophosphate synthase inhibitors: The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use....

20060052348 - Oxazolo-naphthyl acids: e

20060052349 - Pyrrolo-naphthyl acids and methods for using them:

20060052350 - Crystalline forms of 1,24(s)-dihydroxy vitamin d2: Provided are novel crystalline forms of 1,24-(S)-dihydroxy vitamin D2, including hydrates and solvates, and methods for making them. Also provided are pharmaceutical and nutraceutical compositions containing the novel crystalline forms....

20060052352 - Mixtures or organic compounds for the treatment of airway diseases: A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from...

20060052351 - Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress: Disclosed is the use of a composition comprising a combination of diacylglycerol(s) (DAG), mainly 1,3-diacylglycerol(s), and phytosterol and/or phytostanol ester(s) (PSE) dissolved or dispersed in edible oil and/or edible fat, particularly olive, canola and fish oil, in the manufacture of nutritional supplements and orally administrable pharmaceutical preparations which are capable...

20060052353 - Topical dermatological formulations and use thereof: A topical formulation of an androstane steroid compound of improved solubility in combinations of the solvents propylene glycol and propylene carbonate....

20060052354 - Methods for treating migraine: This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating migraine in a subject....

20060052356 - Pharmacological methods to modulate oxygen consumption: Methods of modulating oxygen consumption in tissues are provided. In particular, the methods involve the administration of agents that transiently inhibit protein synthesis. The methods are used to treat ischemia and reperfusion-related injuries by temporarily decreasing oxygen consumption needs, and/or by inhibiting inflammation that results from reperfusion....

20060052355 - Process for preparing 3-chloromethyl-1,2,4-triazolin-5-one: The present invention is directed to processes for the preparation of 3-chloromethyl-1,2,4-triazolin-5-one. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity. Also disclosed are novel semicarbazide salts and the preparation thereof, which are intermediates for the preparation of 3-chloromethyl-1,2,4-triazolin-5-one....

20060052357 - Organometallic anti-tumour agent: e

20060052358 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators....

20060052359 - 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones: e

20060052360 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed....

20060052361 - Nitrogen-containing fused ring compound and use thereof as hiv integrase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an...

20060052362 - Skeletal muscle protecting agent: The present invention provides a novel drug which is useful as a skeletal muscle protecting agent comprising a compound having inhibitory activity against squalene synthase or a salt thereof, or a prodrug thereof....

20060052363 - Haloperidol analogs: B is an aza- or diaza-bicyclo group, which effectively maintains the distance between the moieties connected thereby such that the compound is incapable of metabolizing to BCPP+ like species; and Z is —CH— or N; and pharmaceutically acceptable salts, esters, derivatives, metal complexes, conjugates and prodrugs thereof....

20060052364 - Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors: A pharmaceutical composition for treatment of pain, comprises in combination oxcarbazepine or derivative thereof as defined and a COX-2 inhibitor for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from pain, comprising administering to the patient an effective amount of oxcarbazepine or derivative...

20060052365 - Protease inhibitors: p

20060052366 - Pyridine derivatives as fungicidal compounds: Compound of general formula (I): Process for preparing thus compound. Novel intermediate of general formula (E): for the preparation of compound of general formula (I) Fungicidal composition comprising a compound of general formula (I). Method for treating plants by applying a compound of general formula (I) or a composition comprising...

20060052367 - Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the...

20060052368 - Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists: s

20060052369 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation...

20060052370 - Methods and compositions for treating nociceptive pain: The present invention provides methods and compositions useful for the treatment and prevention of pain....

20060052371 - 1,3-benzothiazinone derivatives, process for producing the same and use thereof: e

20060052372 - Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders: Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia,...

20060052374 - Amino-tetrazole analogues and methods of use: m

20060052373 - Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides:

20060052375 - Bis-alkylbenzylamines: Compounds of Formula (1), wherein R1 is hydrogen; C1-C18alkyl; trifluoromethyl; C3-C8cycloalkyl; phenylC1-C5alkyl; phenyl-C1-C5alkoxy; mono- or di-N-C1-C5alkamino-C1-C5alkyl; amino-di-N-C1-C5alkylamino-C1-C5alkyl; C1-C5alkoxy-C1-C5alkyl; R2 is C2-C20alkyl; hydroxy-C1-C20alkyl; phenyl; phenyl-C1-C5alkyl; phenyl-C1-C5alkoxy; mono- or di-N-C1-C5alkylamino-C1-C5alkyl; amino-di-N-C1-C5alkylamino-C1-C5alkyl; or heteroaryl-C1-C5alkyl; or R1 and R2 together with the nitrogen atom bonding them form a 5- to 7-membered monocyclic heterocyclic ring;...

20060052376 - Carboxamides: Novel compounds of the formula (I), in which D, W, X, Y, T, m and R1 have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours....

20060052377 - Benzyl morpholine derivatives: A compound of formula (I) (I) wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R′ H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof....

20060052378 - Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: c

20060052379 - Pyridazin-3(2h)-one derivatives as pde4 inhibitors: New pyridazin-3(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4....

20060052380 - Novel compounds: The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where...

20060052381 - Solubilized topoisomerase poisons: A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic...

20060052382 - 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also...

20060052383 - New dihydropteridione derivatives, process for their manufacture and their use as medicament: e

20060052384 - Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia: This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines and their use in therapy....

20060052385 - 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors: A class of 8-fluoroimidazo[1,2-α]pyridine derivatives, substituted at the 3-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions...

20060052386 - Sigma ligands for neuronal regeneration and functional recovery: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which...

20060052387 - Organic compounds: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2ylamino)phenyl]benzamide of the formula (I): or a pharmaceutically acceptable salt thereof for the treatment of inflammation....

20060052388 - Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing amines and amides of formula A as the active ingredient are described. The amines and amides of formula A are useful in the treatment of disorders and diseases associated with NPY receptor subtype...

20060052389 - Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects: The invention generally relates to compositions and methods with tramadol and an opioid antagonist to enhance analgesic potency and/or attenuate one or more adverse effects of tramadol, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence) or pruritis. This invention relates to compositions and methods...

20060052391 - Method for the treatment of attention deficit hyperactivity disorder: The invention relates to a method for the treatment of Attention Deficit Hyperactivity Disorder comprising the administration of a therpeutically effective amount of flibanserin....

20060052390 - Treatment of multiple myeloma by p38 map kinase and proteasome inhibition: The present invention provides a method to treat multiple myeloma by the co-administration of one or more p38 MAP kinase inhibitors with one or more proteosome inhibitors....

20060052392 - Isoindoline derivative: e

20060052393 - Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase: Piperazinyl- or piperidinylamine-sulfamic acid amides and their use for the manufacture of a medicament in diseases mediated by the action of steriod sulfatase....

20060052394 - Capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers....

20060052395 - Capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers....

20060052396 - Arylamines for the treatment of conditions associated with gsk-3: The present invention relates to new compounds of formula (I) wherein Z, Y, X, P, Q, R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A, m and n are defined as in any one of claims 1 to 3, a process for their preparation and...

20060052397 - Carbamate-substituted pyrazolopyridines: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction....

20060052398 - Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same: e

20060052399 - Oxazolidinone derivatives as antibacterial agents: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydsolysable ester thereof: formula (I) wherein C is selected from D and E, formula (D), formula (E) R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected...

20060052400 - Thienopyriminediones and their use in the modulation of autoimmune disease: The invention relates to thienopyrimidinediones of formula (1) wherein R1 and R2 each independently represent a C1-6akyl, C3-6alkyl, C3-6alkenyl, C3-5cycloalkylC1-3alkyl or C3-6cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms R3 is a group CO-G or SO2-G where G is a 5- or 6-membered ring...

20060052401 - Method of female sexual enhancement: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, testing the blood of the woman to determine the levels of free estradiol and free testosterone therein, assuring that the woman's blood includes free estradiol with a first predetermined range and free testosterone...

20060052402 - Method of female sexual enhancement: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, testing the blood of the woman to determine the levels of free estradiol and free testosterone therein, assuring that the woman's blood includes free estradiol with a first predetermined range and free testosterone...

20060052403 - Novel adenine compound and use thereof: [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is...

20060052404 - Pharmaceutical formulations comprising substituted xanthine compounds: The present invention provides novel pharmaceutical compositions comprising substituted xanthine compounds useful for the treatment of cystic fibrosis and other diseases, and methods of use thereof....

20060052405 - Hair loss prevention: Compositions to prevent or reduce hair loss, allowing the body to maintain normal, healthy hair growth, comprising a penetration enhancer together with a testosterone blocker or a vascular enhancer, or both....

20060052408 - Cyclopropyl compounds as ccr5 antagonists: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency...

20060052406 - Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor: There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in...

20060052407 - Novel crystals of triazaspiro [5.5] undecane derivative: The present invention relates to a new crystal of triazaspiro[5.5]undecane derivatives. The crystal of a non-solvate of (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-[4-(4-carboxyphenyloxy)phenylmethyl]-1,4,9-triazaspiro[5.5]undecane hydrochloride have safety as drug substance, and have possibility to supply at large scale. And the crystal have an antagonistic activity against the interaction between chemokine and chemokine receptor, therefore, it is...

20060052409 - Therapeutic or preventive agent for nausea/vomiting: e

20060052410 - 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents:

20060052411 - Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor: wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(═O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like;...

20060052412 - 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity: e

20060052413 - Novel piperidine derivatives as modulators of chemokine receptor ccr5: Compounds of formula (I): wherein R1, R2, R3, R4, n, A and X are defined above; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal)....

20060052414 - Compositions and methods for treating or preventing hepadnaviridae infection: The present disclosure relates generally to the use of certain castanospermine esters to treat or prevent infections caused by Hepadnaviridae, particularly infections caused by hepatitis B virus (HBV), and to the use of such compounds to examine the biological mechanisms of HBV infection....

20060052415 - N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form: The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable...

20060052416 - 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof: 2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed....

20060052417 - Indazolamides with analgesic activity: An indazolamide (I), wherein X, R1, R2, R3, R4, R5, R6, R7 and R8 have the meanings given in the description, and addition salts thereof with a pharmaceutically acceptable acid, a method for the preparation thereof and a pharmaceutical composition containing the same....

20060052418 - Viral polymerase inhibitors:

20060052420 - Thiazolo-naphthyl acids:

20060052419 - Use of pyridly amides as inhibitors of angiogenesis: The invention relates to the use of derivatives of Formula I in the manufacture of a pharmaceutical composition for the treatment of a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred, and to the prevention thereof. (I)...

20060052421 - Conjugation agent: are described, wherein Sx is —S—, —SO— or —SO2—; Rs is a carbon-containing substituent that does not include a cyano group; each R is a substituent, with at least one R having a reaction site that is not a carboxylic acid; n is 0-5; each A is carbon or nitrogen,...

20060052422 - 1,2,4-thiadiazole compounds and arthropod controlling composition containing the same: wherein, R1 represents C3-C7 alkynyl that may be substituted with halogen atom; R2 represents C3-C8 cycloalkyl which may be substituted with C1-C4 alkyl, halogen atom and trifluoromethyl or the like; A1 represents a single bond, C1-C2 alkylene or C2-C3 alkylidene. The 1,2,4-thiadiazole compound has an excellent arthropod controlling activity, and...

20060052423 - Peptide deformylase inhibitors: Novel PDF inhibitors and novel methods for their use are provided....

20060052424 - Lactacystin analogs: Compounds related to lactacystin and lactacystin β-lactone, pharmaceutical compositions containing the compounds, and methods of use....

20060052425 - Method for modulating microbial quorum sensing: The present invention provides compositions and methods for modulating bacterial quorum sensing using antagonist or agonist compounds. Further, the present invention provides methods of treating or preventing microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens....

20060052426 - Acylaminothiazole derivatives, their preparation and their therapeutic use: e

20060052427 - N-phenylbenzamide derivatives as drugs for the treatment of copd: wherein R1 is cyano, nitro, halogen, hydroxy, C1-C4 alkyl, methoxy or tetrazol-5-yl group, R2 is hydrogen, hydroxy or methoxy, R3 is a tetrazol-5-yl group or hydrogen, R4 and R5 are hydrogen if R3 is tetrazol-5-yl group, or R4 and R5 are independently selected from the group consisting of carboxy, methoxycarbonyl,...

20060052428 - Neurological functions: The present invention relates to materials and methods for treating neurological diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems....

20060052429 - Oromucosal formulation and process for preparing the same: e

20060052430 - Antihistamines for increased tolerance to extreme heat: Histamine receptor antagonists are administered to delay the onset of or prevent heat stroke in mammals. H2 receptor antagonists including cimetidine, famotidine, nizatidine, and ranitidine are administered to the mammals prior to the exposure of the mammal to stress conditions, such as temperature, environmental, drug, exercise, or combinations thereof. The...

20060052431 - 5-hydroxy indazole derivatives for treating glaucoma: 3-(2-aminoethyl)-1H-indazol-5-ols useful for treating elevated intraocular pressure and glaucoma are disclosed....

20060052432 - Pharmaceutical compositions with improved dissolution: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining...

20060052433 - Compound: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula (I) (wherein X is —SO3H; n, p, q and r are each independently...

20060052434 - Pyrrolizine compounds useful as anti-inflammatory agents: e

20060052435 - Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction: The use of a composition comprising a selective dopamine D3 receptor agonist, wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay, in the preparation of a...

20060052436 - Pyrroloterpenes and use of the same as antimicrobial and anticancer agents: Disclosed herein are novel pyrroloterpene compounds and methods for obtaining these compounds. Also disclosed are methods of treating cancer and bacterial infections using the novel pyrroloterpene compounds....

20060052437 - Combination of an hmg-coa reductase inhibitor and a nitrate ester: The present invention relates to the therapeutical combination of an HMG-CoA reductase inhibitor (statin) and a nitrate ester and is useful mainly for the preparation of medicaments for the prevention and treatment of coronary diseases as myocardial infarction and cerebrovascular diseases as stroke. Particularly, as a nitrate ester, a nitrate...

20060052438 - Bioactive compounds and methods of uses thereof: e

20060052439 - Salvinorin derivatives and uses thereof: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions....

20060052440 - Medicinal composition for treating sudden deafness: The pharmaceutical composition of the present invention for treating sudden deafness containing, as an active ingredient, isoflavone aglycone derived from soybean germ can be used to prevent sudden deafness in humans by manifesting an action that is effective in treating disease in humans. The pharmaceutical composition for treating sudden deafness...

20060052441 - Procyanidin and nitric oxide modulator compositions: This invention relates to an article of manufacture comprising a polymeric compound of formula An and an additional NO-modulating agent and method of use thereof. Also disclosed and claimed is a method of making an article of manufacture comprising of the polymeric compound of formula An....

20060052442 - Cyanomethyl trithiocarbonates as nematicides: The present invention relates to the use of compounds of formula (I), wherein R is C1-C8-alkyl, unsubstituted or substituted with 1, 2 or 3 radicals selected from the group consisting of halogen, amino, nitro, cyano, C1-C4-alkenyl, C1-C4-haloalkenyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, 5- to 10-membered heteroaryl containing as ring members 1, 2,...

20060052444 - Arthropod controlling agent: wherein R1 denotes a hydrogen atom or methyl, R2 denotes methyl or CH═CR21R22 wherein R21 and R22 independently denote a hydrogen atom or methyl, and R3 denotes a hydrogen atom, methyl or methoxymethyl, and said ester compound is supported on a polyolefin type resin, wherein the polyolefin type resin contains...

20060052443 - Compositions and devices for prevention of termite, pest and fungi infestation: The invention provides compositions, devices, and methods for the control of Termites, General Pests and Fungi, such compositions and devices comprising one or more of Phenothrin, a Borate, and a Plant Oil or a derivative thereof....

20060052445 - Diarylsulfones as 5-ht2a antagonists: e

20060052446 - Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders: Compositions, dietary supplements and medical foods for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ5 desaturase, and optionally stearidonic acid or ω−3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based...

20060052447 - Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders: m

20060052448 - Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of treating diseases of the nervous system and/or to prevent against neuronal degeneration due to defective intracellular...

20060052449 - Novel mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and...

20060052450 - Use of l-carnitine for the treatment of cardiovascular diseases: The use of L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicine useful for reducing the number of deaths caused by acute myocardial infarction and for improving the short-and-long-term prognosis in the patients treated with it, in which L-carnitine is administered parenterally within...

20060052451 - Method: A perfluoroctanoic acid or a salt or an ester thereof, perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof, or perfluoroctane are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of...

20060052452 - Phenolic antiseptic compositions and methods of use: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including an antiseptic selected from the group consisting of halogenated phenols, bisphenols, diphenyl ethers, anilides and derivatives thereof, and combinations thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or...

20060052453 - Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient: t

20060052454 - Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders: A method of treating or preventing a subject's health problem that is related to an underlying disorder in the functioning of the metabolic system of the subject includes the step of administering a therapeutically effective dosage of glycine. For health problems associated with the subject's bones, cartilage or connective tissue,...

20060052455 - Composition for preventing treating the xepression of clinical symptom in disease caused by mitochondrial dysfunction: In this application is disclosed an excellent composition for preventing and/or treating the expression of clinical symptoms in a disease caused by mitochondrial dysfunction, characterized in that said composition is an orally administrable composition containing L-arginine as an active ingredient....

20060052456 - Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells: The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase, for the preparation of a medica ment for increasing the number of islets of Langerhans cells, which is intended especially for the prevention and/or treatment of diabetes....

20060052457 - Use of ppar alpha agonists for the treatment of vascular and renal diseases: Activation of peroxisome proliferator activated receptor alpha (PPARα) by administration of therapeutic amounts of a PPARα agonist, WY-14643, inhibits the proliferation of vascular smooth muscle cells, hepatoma cells and human renal proximal tubule cells. WY-14643 may be applicable as a medicament for the treatment of proliferative vascular disease (atherosclerosis, hypertension),...

20060052458 - Preventive or remedy for intrauterine late embryonic development or pregnancy toxemia: t

20060052459 - Antifungal medicaments comprising arylamidine derivatives: The subject of the present invention is novel antifungal medicaments based on N2-phenylamidine derivatives and optionally at least one antifungal synergistic agent....

20060052460 - Latent reactive blood compatible agents: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function...

20060052461 - New 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17beta-hydroxy steroid dehydrogenase type 1: r

20060046956 - Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease....

20060046957 - Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain....

20060046962 - Absorption enhancers for drug administration: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via...

20060046958 - Compositions and methods comprising prostaglandin related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia: Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence of hyperemia....

20060046963 - Compound for inhibiting the influx of polymorphonuclear leukocytes (pmns) in a tissue, its selection, pharmaceutical compositions and use: The invention relates to a compound suitable for inhibiting the influx of polymorphonuclear leukocytes (PMNs) into a tissue involved in a chronic inflammatory disease. The compound according to the invention is capable of forming a complex with N-acetyl-Pro-Gly-Pro. The invention also relates to a method of selecting such a compound,...

20060046960 - Controlled and directed local delivery of anti-inflammatory compositions: The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by controlled and directed delivery of one or more biological response modifiers to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by implantable or...

20060046961 - Controlled and directed local delivery of anti-inflammatory compositions: The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by controlled and directed delivery of one or more biological response modifiers to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by implantable or...

20060046959 - Novel leptin antagonist: The present invention relates to an antagonist or inhibitor of leptin signaling via the leptin receptor. The leptin antagonist binds to the leptin receptor, but is unable to induce JAK-STAT signal transduction via the leptin receptor. By binding to the leptin receptor, the leptin antagonist impairs binding of leptin to...

20060046964 - Pharmaceutical formulations and methods: Stable sodium ferric carbohydrate complex intravenous formulations that are essentially free of sucrose or another disaccharide, methods of making such formulations, and methods for treating anemic conditions in a mammal by administering such compositions....

20060046966 - Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and...

20060046965 - Hepatitis c inhibitor dipeptide analogs: e

20060046967 - Prodrugs containing novel bio-cleavable linkers: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of...

20060046968 - Prodrug substituted benzoxazoles as estrogenic agents: e

20060046969 - Antibacterial compositions for drug administration: An antibacterial composition having at least one alkyl glycoside, at least one saccharide, and at least one therapeutic agent, wherein the alkyl glycoside has an alkyl chain length from about 12 to about 14 carbon atoms and wherein the saccharide has antibacterial activity, thereby providing for a composition having antibacterial...

20060046970 - Topical otic compositions and methods of topical treatment of prevention of otic infections: A topical otic composition containing an azalide antibiotic. A topical otic composition containing an azalide antibiotic and an medicament. A topical otic composition containing an azalide antibiotic and a polymer suspending agent. And methods for treating or preventing infections in the ear using azalide antibiotic compositions....

20060046971 - Treatment of transformed or infected biological cells: The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method...

20060046972 - Cytotoxic nucleoside analog compound 003 for treating cancer: The present invention provides pharmaceutical compositions comprising Compound 003 or metabolites thereof in combination with one or more carboxylesterase inhibitors. The invention provides methods for inhibiting cellular proliferation associated with proliferative cell disorders in a subject by administering Compound 003 or metabolites thereof. The invention also provides methods for arresting...

20060046973 - Compositions containing 5-amino-2-hydroxybenzoic acid and a reducing sugar: Compositions comprising 5-amino-2-hydroxybenzoic acid (5-amino salicylic acid, mesalamine) and a reducing sugar, e.g., lactose, undergo the Maillard and other chemical reactions and produce, in the case of lactose, a degradant 5-[2-Formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl]-2-hydroxybenzoic acid. Inventors have developed means to contain and/or reduce the formation of degradants of 5-amino-2-hydroxybenzoic acid....

20060046974 - N-acyl modified polysaccharides and pharmaceutical compositions comprising same: This invention relates to novel N-acyl modified polysaccharides and pharmaceutical compositions comprising the modified polysaccharides. Further the invention relates to processes for using such compounds to inhibit lipases, to lower cholesterol, to lower the absorption of dietary fat, or as a dietary fiber supplement. In a preferred aspect of the...

20060046976 - Method for increasing the bone mineral density and bone micro-architecture or connectivity of a mammal using n-acylated glucosamines: i

20060046975 - Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis: A method for preparing a medical solution, comprising the steps of a) providing a solution comprising one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container in a concentration from 15% by weight to 40% by weight, with the basis of the solution in...

20060046977 - Furanopyridine derivatives and methods of use: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant,...

20060046978 - Novel compounds that inhibit dipeptidyl peptidase (dpp-iv) and neprilysin (nep) and/or angiotensin converting enzyme (ace): This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof...

20060046980 - Novel phosphorus-containing thyromimetics: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and...

20060046979 - Organic compounds: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b)...

20060046981 - Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof: s

20060046982 - Orthomolecular medical use of l-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease: This invention embodies use of exogenous L-citrulline not only for support of capillary endothelial function, by L-citrulline bioconversion to plasma L-arginine to provide more cell substrate for enzymatic generation of nitric oxide, but also for providing more L-arginine in cellular microenvironments including that in acidified endosomes and lysosomes for potential...

20060046983 - Inhibitors of hcv replication: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds....

20060046984 - Novel gamma-lactams as beta-secretase inhibitors: or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure...

20060046985 - Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors: Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful...

20060046986 - Cytokine inhibitors: t

20060046987 - Substituted quinazoline derivatives and their use as inhibitors: The use of a compound of formula (I) or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6alkyl; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2, R3, R4 are independently selected from various specified...

20060046988 - Methoprene formulations for the control of tick infestations: The present invention relates to a composition and process, in particular for controlling ticks on animals, characterized in that the composition includes, on the one hand, at least one compound of IGR (insect growth regulator) type, in doses and proportions which are parasiticidally effective on ticks, in a fluid vehicle...

20060046990 - New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions: e

20060046989 - New dihydropteridione derivatives, process for their manufacture and their use as medicament:

20060046991 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors:

20060046992 - Heterobicyclic compounds: [wherein X—Y-Z represents R5N—C═O (wherein R5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted lower alkynyl), etc; R1 and R2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower...

20060046993 - Crystalline polymorphic form of irinotecan hydrochloride: This invention relates to a novel crystalline polymorphic form of irinotecan hydrochloride. A process for preparing this novel polymorphic form, pharmaceutical compositions comprising it as an active ingredient and the use of the same and its pharmaceutical compositions as a therapeutic agent is also within the scope of the present...

20060046994 - Process for preparing 3-oxo-4-aza-5-alpha-androstane-17-carboxylic acid: i

20060046995 - Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents:

20060046996 - Method for treating hyperlipidemia: Provided is a method for treating hyperlipidemia or hypercholesterolemia, which comprises administering effective doses of ezetimibe and pitavastatin or a salt or lactone derivative thereof....

20060046997 - 6-alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations: This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R1a, R1b, R2a, R3a, R3b, R4, R5, R6, R7, A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli...

20060046998 - Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease: The present invention relates to compositions and methods for initial treatment of GERD and LPRD using a proton pump inhibitor drug administered concomitantly with a histamine H2 receptor inhibitor, either transdermally or orally....

20060046999 - Monocyclic aroylpyridinones as antiinflammatory agents: The present invention relates to monocyclic aroylpyridinones, processes for their preparation, and their use in medicaments, especially for the treatment of COPD: (formula I)....

20060047000 - Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is...

20060047001 - Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents: The present invention is directed to novel benzo-fused heteroaryl sulfamide derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders....

20060047002 - Process for the preparation of 4,5-diamino shikimic acid derivatives: R3, R4 are independent of each other H or an alkanoyl, with the proviso that not both R3 and R4 are H. 4,5-diamino shikimic acid derivatives of formula I, especially the (3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester and its pharmaceutically acceptable additional salts are potent inhibitors of viral neuraminidase....

20060047003 - Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis: This patent discloses a method of ameliorating a hearing loss, collateral damage of chemotherapy, or mucositis in a mammal, comprising administering a composition comprising a substituted fullerene to the mammal afflicted with the hearing loss, collateral damage of chemotherapy, or mucositis or potentially afflicted with the hearing loss, collateral damage...

20060047004 - Hexim1 as a suppressor of hiv replication and cardiac hypertrophy: Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding....

20060047005 - Compositions containing n,n,n',n'-tetrakis(hydroxyalkyl)diamine-or n,n,n',n'-tetrakis(hydroxyalkoxy)diamine-based buffers: The use of compositions containing one or more antimicrobial agents with one or more (hydroxyalkyl)diamine-based buffers, (hydroxyalkoxy)diamine-based buffers or combinations thereof to disinfect and/or preserve medical devices is described. Solutions containing one or more antimicrobial agents with one or more (hydroxyalkyl)diamine-based buffers, (hydroxyalkoxy)diamine-based buffers or combinations thereof and methods of...

20060047006 - Compositions containing trialkanolamine alkoxylate buffer: The use of compositions containing one or more antimicrobial agents with one or more trialkanolamine alkoxylate buffers to disinfect and/or preserve medical devices is described. Solutions containing one or more antimicrobial agents with one or more trialkanolamine alkoxylate buffers and methods of making and using the same are also described....

20060047007 - Method for treating urinary disorders: The present invention relates to a method, preferable an oral method, for treating urinary disorders, such as unstable or overactive bladder, while minimizing the occurrences of dry mouth, dyspepsia and reduced stream of tears. The methods of the present invention comprise orally administering to a mammal, preferably a human, a...